NEW YORK (GenomeWeb News) — Beijing-based genomics research services company SinoGenoMax will offer Cogenics’ genotyping services in China, Cogenics' parent company, Clinical Data, said today.
"Our partnership with SinoGenoMax provides us with an established presence in China and an experienced international service partner who operates with similar platforms and high quality standards," Cogenics Global Manager Michael Lutz said in a statement. "The extensive pharmaceutical and biotechnology infrastructure and large number of clinical trials conducted in China make this an increasingly important market for clinical genotyping services."
SinoGenoMax CEO Danny Ching said the partnership also "represents a significant opportunity for SinoGenoMax to widen its international spectrum."
Cogenics has facilities in North Carolina, Texas, the United Kingdom, France, and Germany.